高流量鼻导管撤除:谁、何时、如何撤
本文探讨高流量鼻导管(HFNC)在急性呼吸衰竭患者中的撤除策略。HFNC使用增加,但指导其撤除的高质量证据缺乏;何时及如何降低流量、吸入氧浓度(FiO2)或两者同时降低常由临床医生自行决定,缺乏明确最优方法。未能适时降低HFNC支持可能导致ICU/住院时间延长、医疗费用增加及有限医院资源可用性降低。作者以提高住院急性呼吸衰竭患者护理效率和资源利用为目标,提出以「撤除」(类似机械通气患者的自主呼吸试验)为重点、基于生理学指导的逐步撤除HFNC标准化方法。
要点
- HFNC是急性呼吸衰竭患者的一线治疗,但指导其撤除的高质量证据缺乏。
- 何时及如何降低流量、FiO2或两者同时降低常由临床医生自行决定,缺乏明确最优方法。
- 未能适时降低HFNC支持可能导致ICU/住院时间延长、医疗费用增加及有限医院资源可用性降低。
- 作者提出以「撤除」为重点、基于生理学指导的逐步撤除HFNC标准化方法,目标为提高护理效率和资源利用。
适用人群与场景
- 住院的急性呼吸衰竭患者。
处置流程与药物剂量
- 作者提出以「撤除」为重点的标准化HFNC撤除方法,类似机械通气患者的自主呼吸试验,采用基于生理学指导的逐步撤除方式;具体步骤和阈值原文未详述。
证据类型、等级与局限
- 证据类型:专家意见(Chest综述)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者提出以生理学为指导的逐步撤除HFNC标准化方法,旨在提高护理效率和资源利用;具体实施方案原文未详述。
指南或共识出处
- Chest
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「研究设计与关键结果」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
High-flow nasal cannula (HFNC) is a first-line therapy for patients with acute respiratory failure. Despite increased HFNC utilization over recent years-accelerated in part by the COVID-19 pandemic-high-quality evidence to guide HFNC discontinuation is lacking. Decisions about when and how quickly to reduce flow rate, Fio2, or both simultaneously are frequently left to clinicians' discretion without clear guidance on an optimal approach. Failure to de-escalate HFNC support when clinically appropriate has many potential consequences, such as prolongation of ICU/hospital length of stay, increased health care costs, and reduced availability of limited hospital resources. With the goal of improving care efficiency and resource utilization among hospitalized patients with acute respiratory failure, we propose a standardized approach for HFNC discontinuation focused on "liberation" (similar to spontaneous breathing trials for patients undergoing mechanical ventilation), using a stepwise approach guided by physiology.
参考来源
- Freeman H, Vranas KC, Tuthill S, et al. High-Flow Nasal Cannula Liberation: Who, When, and How? Chest. 2025. PMID: 39929280. doi:10.1016/j.chest.2025.01.037
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。